TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of D-cycloserine on Treatment of PTSD in Youth
Brief Summary: The purpose of this study is to show whether D-cycloserine in combination with cognitive behavioral therapy (CBT) is more effective than CBT plus placebo to reduce symptoms of posttraumatic stress disorder (PTSD) in 7-12 year old children.


Options:
A: Arm Label: Cognitive Behavioral Group Therapy + D-Cycloserine; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive Behavioral Group Therapy (CBGT), Drug: D-Cycloserine | Arm Label: Cognitive Behavioral Group Therapy + Placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Cognitive Behavioral Group Therapy (CBGT), Drug: Placebo | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Group Therapy (CBGT); Assigned to Arm(s): Cognitive Behavioral Group Therapy + D-Cycloserine, Cognitive Behavioral Group Therapy + Placebo | Intervention Type: DRUG; Name: D-Cycloserine; Assigned to Arm(s): Cognitive Behavioral Group Therapy + D-Cycloserine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cognitive Behavioral Group Therapy + Placebo
B: Intervention Type: BEHAVIORAL; Name: Cognitive behavioral therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: D-cycloserine; Assigned to Arm(s): N/A
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: D-Cycloserine, Behavioral: Virtual Reality Exposure Therapy | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Alprazolam, Behavioral: Virtual Reality Exposure Therapy | Arm Label: C; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Virtual Reality Exposure Therapy, Drug: Placebo | Intervention Type: DRUG; Name: D-Cycloserine; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Alprazolam; Assigned to Arm(s): B | Intervention Type: BEHAVIORAL; Name: Virtual Reality Exposure Therapy; Assigned to Arm(s): A, B, C | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): C
D: Arm Label: D-cycloserine plus CBT; Type: ACTIVE_COMPARATOR; Interventions: Drug: D-cycloserine, Behavioral: CBT | Arm Label: Placebo plus CBT; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo pill, Behavioral: CBT | Intervention Type: DRUG; Name: D-cycloserine; Assigned to Arm(s): D-cycloserine plus CBT | Intervention Type: DRUG; Name: Placebo pill; Assigned to Arm(s): Placebo plus CBT | Intervention Type: BEHAVIORAL; Name: CBT; Assigned to Arm(s): D-cycloserine plus CBT, Placebo plus CBT

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: D-cycloserine Adjunctive Treatment for PTSD in Adolescents
Brief Summary: The purpose of this study is to show whether D-cycloserine in combination with cognitive behavioral therapy (CBT) is more effective than CBT plus placebo to reduce symptoms of posttraumatic stress disorder (PTSD) in 13-18 year-old children.


Options:
A: Arm Label: D-cycloserine plus CBT; Type: ACTIVE_COMPARATOR; Interventions: Drug: D-cycloserine, Behavioral: CBT | Arm Label: Placebo pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo pill, Behavioral: CBT | Intervention Type: DRUG; Name: D-cycloserine; Assigned to Arm(s): D-cycloserine plus CBT | Intervention Type: DRUG; Name: Placebo pill; Assigned to Arm(s): Placebo pill | Intervention Type: BEHAVIORAL; Name: CBT; Assigned to Arm(s): D-cycloserine plus CBT, Placebo pill
B: Arm Label: Cognitive-behavioral therapy + placebo; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive-behavioral therapy, Drug: Placebo pill | Arm Label: Cognitive-behavioral therapy + D-cycloserine; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive-behavioral therapy, Drug: D-cycloserine | Intervention Type: BEHAVIORAL; Name: Cognitive-behavioral therapy; Assigned to Arm(s): Cognitive-behavioral therapy + D-cycloserine, Cognitive-behavioral therapy + placebo | Intervention Type: DRUG; Name: D-cycloserine; Assigned to Arm(s): Cognitive-behavioral therapy + D-cycloserine | Intervention Type: DRUG; Name: Placebo pill; Assigned to Arm(s): Cognitive-behavioral therapy + placebo
C: Arm Label: Placebo + Prolonged Imaginal Exposure; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo + Prolonged Imaginal Exposure | Arm Label: Placebo + VR exposure; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (sugar pill) + Virtual Reality Exposure | Arm Label: DCS + Prolonged Imaginal Exposure; Type: ACTIVE_COMPARATOR; Interventions: Drug: DCS (D-Cycloserine ) + Prolonged Imaginal Exposure | Arm Label: DCS+VR exposure; Type: ACTIVE_COMPARATOR; Interventions: Drug: DCS (D-Cycloserine ) + Virtual Reality Exposure | Intervention Type: DRUG; Name: DCS (D-Cycloserine ) + Prolonged Imaginal Exposure; Assigned to Arm(s): DCS + Prolonged Imaginal Exposure | Intervention Type: DRUG; Name: DCS (D-Cycloserine ) + Virtual Reality Exposure; Assigned to Arm(s): DCS+VR exposure | Intervention Type: DRUG; Name: Placebo + Prolonged Imaginal Exposure; Assigned to Arm(s): Placebo + Prolonged Imaginal Exposure | Intervention Type: DRUG; Name: Placebo (sugar pill) + Virtual Reality Exposure; Assigned to Arm(s): Placebo + VR exposure
D: Arm Label: D-cycloserine plus CBT; Type: ACTIVE_COMPARATOR; Interventions: Drug: D-cycloserine, Behavioral: CBT | Arm Label: Placebo plus CBT; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo pill, Behavioral: CBT | Intervention Type: DRUG; Name: D-cycloserine; Assigned to Arm(s): D-cycloserine plus CBT | Intervention Type: DRUG; Name: Placebo pill; Assigned to Arm(s): Placebo plus CBT | Intervention Type: BEHAVIORAL; Name: CBT; Assigned to Arm(s): D-cycloserine plus CBT, Placebo plus CBT

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Everolimus Added to Long Acting Octreotide as a Volume Reducing Treatment of Polycystic Livers
Brief Summary: The aim of this study is to reduce polycystic liver volume by treating with octreotide, whether or not combined with everolimus; to assess whether combination therapy of everolimus and octreotide gives a bigger reduction of polycystic liver volume than octreotide monotherapy.


Options:
A: Arm Label: ACE-I + placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Lisinopril, Drug: Placebo | Arm Label: ACE-I + ARB; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lisinopril, Drug: Telmisartan | Intervention Type: DRUG; Name: Lisinopril; Assigned to Arm(s): ACE-I + ARB, ACE-I + placebo | Intervention Type: DRUG; Name: Telmisartan; Assigned to Arm(s): ACE-I + ARB | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): ACE-I + placebo
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Candesartan | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Candesartan and Cilnidipine | Arm Label: C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Candesartan plus non-CCB agents | Intervention Type: DRUG; Name: Candesartan; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Candesartan and Cilnidipine; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Candesartan plus non-CCB agents; Assigned to Arm(s): C
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: OPC-41061 | Intervention Type: DRUG; Name: OPC-41061; Assigned to Arm(s): 1
D: Arm Label: Everolimus + octreotide LAR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Everolimus, Drug: Octreotide LAR | Arm Label: Octreotide LAR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Octreotide LAR | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Everolimus + octreotide LAR | Intervention Type: DRUG; Name: Octreotide LAR; Assigned to Arm(s): Everolimus + octreotide LAR, Octreotide LAR

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Double-blind, Randomized, Placebo-controlled, Parallel Group and Dose-finding, Multicentric, Safety and Efficacy Study With Intramuscular Injections of NV1FGF in Subjects With Intermittent Claudication
Brief Summary: The primary objective is to assess safety and efficacy of two different doses of NV1FGF as compared to placebo.

The secondary objective is to assess the pharmacokinetics of NV1FGF and FGF-1 protein.


Options:
A: Intervention Type: DRUG; Name: XRP0038 (NV1FGF); Assigned to Arm(s): N/A
B: Arm Label: placebo; Type: EXPERIMENTAL; Interventions: Drug: placebo | Arm Label: NV1FGF 16 mg; Type: EXPERIMENTAL; Interventions: Drug: XRP0038 (NV1FGF) | Arm Label: NV1FGF 32 mg; Type: EXPERIMENTAL; Interventions: Drug: XRP0038 (NV1FGF) | Intervention Type: DRUG; Name: XRP0038 (NV1FGF); Assigned to Arm(s): NV1FGF 16 mg, NV1FGF 32 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
C: Arm Label: Riferminogene pecaplasmid; Type: EXPERIMENTAL; Interventions: Biological: riferminogene pecaplasmid | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo (for riferminogene pecaplasmid) | Intervention Type: BIOLOGICAL; Name: riferminogene pecaplasmid; Assigned to Arm(s): Riferminogene pecaplasmid | Intervention Type: BIOLOGICAL; Name: Placebo (for riferminogene pecaplasmid); Assigned to Arm(s): Placebo
D: Arm Label: A: GM-CSF + supervised treadmill exercise therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Supervised Treadmill Exercise Therapy, Drug: granulocyte macrophage colony stimulating factor (GM-CSF) | Arm Label: B: GM-CSF + attention control group; Type: ACTIVE_COMPARATOR; Interventions: Other: Health education sessions (Control), Drug: granulocyte macrophage colony stimulating factor (GM-CSF) | Arm Label: C: placebo + supervised exercise therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supervised Treadmill Exercise Therapy | Arm Label: D: placebo + attention control group; Type: PLACEBO_COMPARATOR; Interventions: Other: Health education sessions (Control) | Intervention Type: BEHAVIORAL; Name: Supervised Treadmill Exercise Therapy; Assigned to Arm(s): A: GM-CSF + supervised treadmill exercise therapy, C: placebo + supervised exercise therapy | Intervention Type: OTHER; Name: Health education sessions (Control); Assigned to Arm(s): B: GM-CSF + attention control group, D: placebo + attention control group | Intervention Type: DRUG; Name: granulocyte macrophage colony stimulating factor (GM-CSF); Assigned to Arm(s): A: GM-CSF + supervised treadmill exercise therapy, B: GM-CSF + attention control group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Double-blind, Randomized, Placebo-controlled, Parallel Group and Dose-finding, Multicentric, Safety and Efficacy Study With Intramuscular Injections of NV1FGF in Subjects With Intermittent Claudication
Brief Summary: The primary objective is to assess safety and efficacy of two different doses of NV1FGF as compared to placebo.

The secondary objective is to assess the pharmacokinetics of NV1FGF and FGF-1 protein.


Options:
A: Arm Label: NV1FGF 500 μg; Type: EXPERIMENTAL; Interventions: Drug: XRP0038 (NV1FGF) | Arm Label: NV1FGF 2000 μg; Type: EXPERIMENTAL; Interventions: Drug: XRP0038 (NV1FGF) | Arm Label: NV1FGF 4000 μg; Type: EXPERIMENTAL; Interventions: Drug: XRP0038 (NV1FGF) | Intervention Type: DRUG; Name: XRP0038 (NV1FGF); Assigned to Arm(s): NV1FGF 2000 μg, NV1FGF 4000 μg, NV1FGF 500 μg
B: Arm Label: placebo; Type: EXPERIMENTAL; Interventions: Drug: placebo | Arm Label: NV1FGF 16 mg; Type: EXPERIMENTAL; Interventions: Drug: XRP0038 (NV1FGF) | Arm Label: NV1FGF 32 mg; Type: EXPERIMENTAL; Interventions: Drug: XRP0038 (NV1FGF) | Intervention Type: DRUG; Name: XRP0038 (NV1FGF); Assigned to Arm(s): NV1FGF 16 mg, NV1FGF 32 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
C: Intervention Type: DRUG; Name: XRP0038 (NV1FGF); Assigned to Arm(s): N/A
D: Arm Label: Riferminogene pecaplasmid; Type: EXPERIMENTAL; Interventions: Biological: riferminogene pecaplasmid | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo (for riferminogene pecaplasmid) | Intervention Type: BIOLOGICAL; Name: riferminogene pecaplasmid; Assigned to Arm(s): Riferminogene pecaplasmid | Intervention Type: BIOLOGICAL; Name: Placebo (for riferminogene pecaplasmid); Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Diabetes Prevention in Women With a Recent History of Gestational Diabetes Mellitus (GDM)
Brief Summary: Many studies have shown that women with a history of gestational diabetes mellitus (GDM) have an increased risk of developing diabetes later in life. The purpose of the study is to test whether a web-based lifestyle intervention program adapted from the NIH sponsored Diabetes Prevention Program (DPP), modified specifically for women with a recent history of GDM, incorporating advice about diet and physical activity, delivered in the first 12 months after delivery will help women lose weight, improve overall health, and decrease their risk factors for type 2 diabetes.


Options:
A: Arm Label: Lifestyle Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Balance after Baby Lifestyle Intervention Program | Arm Label: Post-gestational diabetes mellitus (GDM) Follow-up Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Balance after Baby Lifestyle Intervention Program; Assigned to Arm(s): Lifestyle Intervention group
B: Arm Label: Glycerin suppository; Type: PLACEBO_COMPARATOR; Interventions: Drug: Glycerin Suppository | Arm Label: Belladonna and opioid suppository; Type: EXPERIMENTAL; Interventions: Drug: Belladonna and opioid suppository | Intervention Type: DRUG; Name: Belladonna and opioid suppository; Assigned to Arm(s): Belladonna and opioid suppository | Intervention Type: DRUG; Name: Glycerin Suppository; Assigned to Arm(s): Glycerin suppository
C: Arm Label: Morphine; Type: EXPERIMENTAL; Interventions: Drug: Preservative Free Morphine | Arm Label: Saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline | Intervention Type: DRUG; Name: Preservative Free Morphine; Assigned to Arm(s): Morphine | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): Saline
D: Arm Label: Magnesium sulfate; Type: ACTIVE_COMPARATOR; Interventions: Other: Cold pads soaked in Magnesium sulfate solution | Arm Label: Water; Type: SHAM_COMPARATOR; Interventions: Other: Cold pads soaked in water | Intervention Type: OTHER; Name: Cold pads soaked in Magnesium sulfate solution; Assigned to Arm(s): Magnesium sulfate | Intervention Type: OTHER; Name: Cold pads soaked in water; Assigned to Arm(s): Water

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Diabetes Prevention in Women With a Recent History of Gestational Diabetes Mellitus (GDM)
Brief Summary: Many studies have shown that women with a history of gestational diabetes mellitus (GDM) have an increased risk of developing diabetes later in life. The purpose of the study is to test whether a web-based lifestyle intervention program adapted from the NIH sponsored Diabetes Prevention Program (DPP), modified specifically for women with a recent history of GDM, incorporating advice about diet and physical activity, delivered in the first 12 months after delivery will help women lose weight, improve overall health, and decrease their risk factors for type 2 diabetes.


Options:
A: Arm Label: intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention | Arm Label: Wait-listed control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Intervention; Assigned to Arm(s): intervention
B: Arm Label: Education Home Visits; Type: EXPERIMENTAL; Interventions: Other: Education Home Visits | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Education Home Visits; Assigned to Arm(s): Education Home Visits
C: Arm Label: Lifestyle Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Balance after Baby Lifestyle Intervention Program | Arm Label: Post-gestational diabetes mellitus (GDM) Follow-up Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Balance after Baby Lifestyle Intervention Program; Assigned to Arm(s): Lifestyle Intervention group
D: Arm Label: Breastfeeding Peer Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Breastfeeding Peer Counseling | Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Breastfeeding Peer Counseling; Assigned to Arm(s): Breastfeeding Peer Counseling

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Trial of Patterned Oral Somatosensory Entrainment
Brief Summary: The primary hypothesis is that the preterm infants (26 0/7 to 30 6/7 weeks gestational age) who undergo the NTrainer System® training will transition to full oral feeds faster than the control group (i.e. the study group will be superior to the control).

The secondary hypothesis is that the infants in the NTrainer System® experimental group will have shorter lengths of stay.


Options:
A: Arm Label: Patterned Experience Group; Type: EXPERIMENTAL; Interventions: Behavioral: Patterned Experience | Arm Label: Usual Care Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Patterned Experience; Assigned to Arm(s): Patterned Experience Group
B: Arm Label: EPI experimental; Type: EXPERIMENTAL; Interventions: Device: NTrainer | Arm Label: EPI control; Type: SHAM_COMPARATOR; Interventions: Device: SHAM blind pacifier | Intervention Type: DEVICE; Name: NTrainer; Assigned to Arm(s): EPI experimental | Intervention Type: DEVICE; Name: SHAM blind pacifier; Assigned to Arm(s): EPI control
C: Arm Label: NTrainer® Intervention; Type: EXPERIMENTAL; Interventions: Device: NTrainer® Intervention | Arm Label: Control Intervention; Type: SHAM_COMPARATOR; Interventions: Device: Control Intervention | Intervention Type: DEVICE; Name: NTrainer® Intervention; Assigned to Arm(s): NTrainer® Intervention | Intervention Type: DEVICE; Name: Control Intervention; Assigned to Arm(s): Control Intervention
D: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Other: Intervention group | Arm Label: Control group; Type: SHAM_COMPARATOR; Interventions: Other: Control group | Intervention Type: OTHER; Name: Intervention group; Assigned to Arm(s): Intervention group | Intervention Type: OTHER; Name: Control group; Assigned to Arm(s): Control group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: McFlu2 COLD3 Prevention: A Randomized, Placebo-controlled, Double Blind Trial of Vitamin D and Health Advice for the Prevention of Upper Respiratory Tract Infections in McMaster University Students
Brief Summary: The specific objectives of this investigation are to assess the effectiveness of daily gargling and vitamin D supplementation as preventative measures against incident upper respiratory tract infection (URTI) in students attending McMaster University. Investigators hypothesize that

1. Vitamin D3 supplementation will decrease the incidence of symptomatic upper respiratory tract infections in university students
2. Gargling will decrease the incidence of symptomatic upper respiratory tract infections in university students.


Options:
A: Arm Label: State of the Art strategy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: state-of-the art strategy and extented strategy | Arm Label: extended strategy; Type: EXPERIMENTAL; Interventions: Behavioral: state-of-the art strategy and extented strategy | Intervention Type: BEHAVIORAL; Name: state-of-the art strategy and extented strategy; Assigned to Arm(s): State of the Art strategy, extended strategy
B: Arm Label: Vitamin D and gargling; Type: EXPERIMENTAL; Interventions: Dietary Supplement: cholecalciferol (vitamin D3), Behavioral: Gargling | Arm Label: Vitamin D and general health advice; Type: EXPERIMENTAL; Interventions: Dietary Supplement: cholecalciferol (vitamin D3) | Arm Label: Placebo and general health advice; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: Placebo and gargling; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Gargling, Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: cholecalciferol (vitamin D3); Assigned to Arm(s): Vitamin D and gargling, Vitamin D and general health advice | Intervention Type: BEHAVIORAL; Name: Gargling; Assigned to Arm(s): Placebo and gargling, Vitamin D and gargling | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo and gargling, Placebo and general health advice
C: Arm Label: N95 Respirator; Type: ACTIVE_COMPARATOR; Interventions: Device: N95 Respirator | Arm Label: Medical/surgical mask; Type: ACTIVE_COMPARATOR; Interventions: Device: Medical/surgical mask | Intervention Type: DEVICE; Name: N95 Respirator; Assigned to Arm(s): N95 Respirator | Intervention Type: DEVICE; Name: Medical/surgical mask; Assigned to Arm(s): Medical/surgical mask
D: Arm Label: Green tea; Type: EXPERIMENTAL; Interventions: Dietary Supplement: green tea | Arm Label: water; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: green tea | Intervention Type: DIETARY_SUPPLEMENT; Name: green tea; Assigned to Arm(s): Green tea, water

Answer: B